NRIX (STOCKS)
Nurix Therapeutics, Inc. Common stock
$28.000000
+1.370000 (+5.14%)
Prev close: $26.630000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Arthur T. Sands
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3,237.42M
- Employees
- 286
- P/E (TTM)
- -7.89
- P/B (TTM)
- 6.86
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $36.77M |
| Benefits Costs and Expenses | $284.96M |
| Costs And Expenses | $383.71M |
| Operating Expenses | $397.95M |
| Depreciation and Amortization | $8.60M |
| Research and Development | $340.93M |
| Other Operating Expenses | $52.70M |
| Operating Income/Loss | -$361.18M |
| Income/Loss From Continuing Operations After Tax | -$341.35M |
| Income/Loss From Continuing Operations Before Tax | -$341.62M |
| Income Tax Expense/Benefit | -$271.00K |
| Net Income/Loss | -$341.35M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$341.35M |
| Net Income/Loss Available To Common Stockholders, Basic | -$341.35M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.46 |
| Diluted Earnings Per Share | -$3.46 |
| Basic Average Shares | 308,112,865 |
| Diluted Average Shares | 308,112,865 |
| Assets | $535.54M |
| Current Assets | $456.48M |
| Cash | $443.50M |
| Other Current Assets | $12.98M |
| Noncurrent Assets | $79.06M |
| Fixed Assets | $20.01M |
| Other Non-current Assets | $59.05M |
| Liabilities | $132.91M |
| Current Liabilities | $72.02M |
| Accounts Payable | $12.21M |
| Wages | $13.45M |
| Other Current Liabilities | $46.36M |
| Noncurrent Liabilities | $60.89M |
| Equity | $402.63M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $402.63M |
| Liabilities And Equity | $535.54M |
| Net Cash Flow From Operating Activities | -$293.70M |
| Net Cash Flow From Operating Activities, Continuing | -$293.70M |
| Net Cash Flow From Investing Activities | $19.99M |
| Net Cash Flow From Investing Activities, Continuing | $19.99M |
| Net Cash Flow From Financing Activities | $257.20M |
| Net Cash Flow From Financing Activities, Continuing | $257.20M |
| Net Cash Flow | -$16.51M |
| Net Cash Flow, Continuing | -$16.51M |
| Comprehensive Income/Loss | -$341.43M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$341.48M |
| Other Comprehensive Income/Loss | -$254.25M |